Pro Medicus Limited (PMCUF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 64.70 means the share price is 64.70 times one year of earnings per share; the S&P 500 usually sits near 20-25. Market cap $12.4B is the value of all shares combined. Beta 0.49: the stock has moved about 51% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerPro Medicus Limited (PMCUF) trades at $118.67. Pro Medicus Limited (PMCUF) specializes in healthcare imaging software and services, catering to hospitals and diagnostic imaging groups across multiple regions. Market cap: $12.4B, Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 17, 2026PMCUF stock analysis for 2026: Analysts have set a consensus price target of $155.00 for Pro Medicus Limited, suggesting 30.6% upside from the current price of $118.67. Key factors: analyst coverage, company fundamentals.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
PMCUF: 1/2 scored disciplines lean bullish. Dominant signal: Izzy Englander bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Pro Medicus Limited (PMCUF) Healthcare & Pipeline Overview
Pro Medicus Limited is a leading provider of healthcare imaging software and services, offering innovative solutions to hospitals and diagnostic imaging groups in Australia, North America, and Europe, with a focus on advanced visualization and integration capabilities.
What Is the Investment Thesis for PMCUF?
Pro Medicus Limited is poised for continued growth, driven by its innovative product offerings and expanding market reach. The company boasts an impressive profit margin of 97.6% and a gross margin of 78.4%, indicating strong operational efficiency. With a market capitalization of $12.4B and a P/E ratio of 64.70, Pro Medicus is well-positioned in the competitive landscape of healthcare information services. Key growth catalysts include the increasing demand for advanced imaging solutions, expansion into new geographic markets, and ongoing enhancements to its software capabilities. The company's focus on integrating artificial intelligence into its products could further enhance its competitive advantage. However, potential risks include regulatory challenges and competition from other healthcare technology firms. Investors should monitor these factors closely as they evaluate the company's long-term prospects.
Based on FMP financials and quantitative analysis
PMCUF Key Highlights
Market capitalization of $12.4B reflects strong investor confidence in the company's growth potential.
- Profit margin of 97.6% showcases Pro Medicus's operational efficiency and profitability.
- Gross margin of 78.4% exceeds industry averages, indicating a strong pricing power and cost management.
- P/E ratio of 64.70 suggests that investors are willing to pay a premium for future earnings growth.
- Beta of 0.49 indicates lower volatility compared to the broader market, appealing to risk-averse investors.
Who Are PMCUF's Competitors?
PMCUF is benchmarked below against 4 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ALPMF Astellas Pharma Inc. | $15.45 | -1.28% | $27.7B | — |
| BMXXY bioMérieux S.A. | $8.86 | +4.24% | $10.5B | — |
| FMCQF Fresenius Medical Care AG & Co. KGaA | $44.12 | -14.22% | $11.9B | — |
| GIKLY Grifols, S.A. | $5.75 | 0.00% | $15.1B | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PMCUF's Key Strengths?
High profit margins indicating strong operational efficiency.
- Innovative product offerings that meet the needs of modern healthcare.
- Established presence in multiple international markets.
- Strong brand reputation built over decades of operation.
What Are PMCUF's Weaknesses?
Dependence on a limited number of key products for revenue.
- Relatively small employee base may limit scalability.
- Vulnerability to regulatory changes in healthcare technology.
- Limited market awareness in some geographic regions.
What Could Drive PMCUF Stock Higher?
PMCUF catalyst: Expansion into new geographic markets, particularly in North America and Europe, expected to drive revenue growth.
- Continuous development of innovative healthcare imaging software to meet evolving market demands.
- Strong customer retention rates due to exceptional service and support, enhancing long-term revenue stability.
- Potential integration of AI technologies into existing products to improve diagnostic accuracy and efficiency.
- Strategic partnerships with healthcare providers to enhance product offerings and market reach.
What Are the Key Risks for PMCUF?
Rich valuation — a P/E of 64.70 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.
- Regulatory changes impacting the healthcare technology landscape could affect product development and market access.
- Intense competition from established players and new entrants may pressure pricing and market share.
- Economic downturns could lead to reduced healthcare spending, impacting revenue growth.
- Rapid technological advancements may require continuous investment in R&D to stay competitive.
What Are the Growth Opportunities for PMCUF?
- Growth opportunity 1: The global healthcare imaging market is projected to reach $45 billion by 2027, driven by the increasing demand for advanced imaging technologies. Pro Medicus is well-positioned to capitalize on this growth through its innovative software solutions, which enhance diagnostic accuracy and improve patient outcomes.
- Growth opportunity 2: Expansion into North America and Europe presents significant revenue potential for Pro Medicus. As healthcare providers in these regions increasingly adopt digital solutions, Pro Medicus can leverage its established reputation and advanced product offerings to capture market share.
- Growth opportunity 3: The integration of artificial intelligence into Pro Medicus's imaging software could revolutionize diagnostic processes. By enhancing the speed and accuracy of image analysis, the company can improve clinician efficiency and patient care, positioning itself as a leader in AI-driven healthcare solutions.
- Growth opportunity 4: The ongoing shift towards value-based care in healthcare systems worldwide creates opportunities for Pro Medicus to provide solutions that improve operational efficiencies and patient outcomes. As healthcare providers seek to reduce costs while maintaining high-quality care, Pro Medicus's software can play a critical role.
- Growth opportunity 5: Strategic partnerships with hospitals and diagnostic imaging groups can further enhance Pro Medicus's market presence. By collaborating with key stakeholders in the healthcare ecosystem, the company can develop tailored solutions that address specific needs and drive adoption of its software.
What Are PMCUF's Competitive Advantages?
- Proprietary technology that differentiates Pro Medicus's software from competitors.
- Strong brand reputation established over decades in the healthcare sector.
- High customer retention rates due to exceptional service and support.
- Innovative product offerings that address evolving healthcare needs.
- Established partnerships with leading healthcare institutions enhance credibility.
What Does PMCUF Do?
Founded in 1983 and headquartered in Richmond, Australia, Pro Medicus Limited has established itself as a key player in the healthcare information services industry. The company specializes in developing and supplying advanced healthcare imaging software and services tailored for hospitals, diagnostic imaging groups, and other health entities. Over the years, Pro Medicus has evolved to meet the growing demands of the healthcare sector, particularly in the realm of radiology information systems (RIS), which facilitate efficient practice management and enhance patient care. Their flagship products include Visage RIS, Visage 7, and Promedicus.net, an e-health platform designed to streamline healthcare processes. Pro Medicus is recognized for its proprietary software that supports the visualization of 2-D, 3-D, and 4-D medical images, alongside a robust picture archive and communication system (PACS). The company's offerings extend to mobile applications such as Visage Ease Pro, which allows users to interpret diagnostic imaging studies remotely. With a workforce of 75 employees, Pro Medicus operates not only in Australia but also has a significant presence in North America and Europe, positioning itself as a global leader in healthcare imaging solutions.
What Products and Services Does PMCUF Offer?
- Develops and supplies healthcare imaging software and services.
- Offers radiology information systems (RIS) for practice management.
- Provides visualization capabilities for 2-D, 3-D, and 4-D medical images.
- Delivers picture archive and communication system (PACS) software.
- Offers mobile applications like Visage Ease Pro for remote diagnostics.
- Provides professional services including training, installation, and support.
How Does PMCUF Make Money?
- Generates revenue through the sale of software licenses and subscriptions.
- Offers professional services such as training and installation for additional revenue.
- Provides ongoing support and maintenance services for existing clients.
- Monetizes through partnerships with healthcare providers and institutions.
- Utilizes a SaaS model for certain products, ensuring recurring revenue streams.
What Industry Does PMCUF Operate In?
The healthcare information services industry is experiencing rapid growth, driven by the increasing adoption of digital health solutions and the need for efficient healthcare delivery systems. As hospitals and diagnostic imaging centers seek to enhance patient care and streamline operations, the demand for advanced imaging software like that offered by Pro Medicus is on the rise. The global healthcare IT market is projected to grow significantly, with a focus on integrating innovative technologies such as artificial intelligence and machine learning. Pro Medicus's strong positioning in this evolving landscape, coupled with its commitment to innovation, allows it to compete effectively against peers such as ALPMF, BMXXY, CNONF, FMCQF, and GIKLY.
Who Are PMCUF's Key Customers?
- Hospitals seeking advanced imaging solutions.
- Diagnostic imaging groups looking for efficient practice management.
- Healthcare entities requiring integrated e-health platforms.
- Clinicians and radiologists needing enhanced visualization tools.
- Healthcare organizations focused on improving patient care and operational efficiency.
Research confidence
Enough evidence to be useful, with gaps worth knowing about.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 73 days ago
- ● Covered by analysts
Pro Medicus Limited (PMCUF) Valuation Context
Valued at $12.4B, PMCUF is classified as a large-cap stock.
PMCUF Revenue & Earnings Trend
In Q4 FY2026, PMCUF generated $136.7M in top-line revenue, marking a sequential increase of 9.6%. The company recorded net income of $94.0M, with diluted EPS of $0.90. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this large-cap Healthcare company. Across the four most recent quarters, PMCUF averaged $0.91 in diluted EPS.
Company Profile
Pro Medicus Limited operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Richmond, AU. The company is led by CEO Sam Aaron Hupert. PMCUF has traded publicly since 2021.
Key Financial Metrics
Return on equity for Pro Medicus Limited stands at 72.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 44.0%, showing how much profit it generates from its asset base. PMCUF trades at a trailing price-to-earnings ratio of 64.70, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 0.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.22 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 1.3%, the inverse of the P/E and a quick read on earnings relative to price.
PMCUF Financials
Bull Case vs Bear Case
Bull Case
- High profit margins indicating strong operational efficiency.
- Innovative product offerings that meet the needs of modern healthcare.
- Established presence in multiple international markets.
- Strong brand reputation built over decades of operation.
Bear Case
- Dependence on a limited number of key products for revenue.
- Relatively small employee base may limit scalability.
- Vulnerability to regulatory changes in healthcare technology.
- Limited market awareness in some geographic regions.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 FY2026 | A$137M | A$94M | A$0.90 |
| Q2 FY2026 | A$125M | A$171M | A$1.64 |
| Q4 FY2025 | A$116M | A$63M | A$0.61 |
| Q2 FY2025 | A$97M | A$52M | A$0.49 |
Q4 FY2026 · filed 30 Jun 2026 · Financial Modeling Prep
Based on FMP financials and quantitative analysis · Reported in AUD
PMCUF Latest News
No recent news available for PMCUF.
PMCUF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for PMCUF.
Price Targets
Consensus target: $155.00
PMCUF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for PMCUF; grades run from A+ (80-100) to F (below 30).
Leadership: Sam Aaron Hupert
CEO
Sam Aaron Hupert has been at the helm of Pro Medicus Limited, bringing extensive experience in the healthcare technology sector. With a background in software development and management, he has played a pivotal role in shaping the company's strategic direction. Hupert holds a degree in Computer Science and has worked in various leadership roles within the technology industry prior to joining Pro Medicus.
Track Record: Under Hupert's leadership, Pro Medicus has significantly expanded its market presence, particularly in North America and Europe. His focus on innovation and customer service has resulted in increased revenue and a strong brand reputation in the healthcare imaging sector.
PMCUF OTC Market Information
The OTC Other tier includes companies that do not meet the criteria for higher tiers like OTCQX or OTCQB. These companies may have less stringent reporting requirements and lower liquidity, which can affect trading volumes and investor access.
- OTC Tier: OTC Other
- Limited financial disclosure compared to companies on major exchanges.
- Potential for lower trading volumes, affecting liquidity.
- Increased volatility due to less regulatory oversight.
- Risk of fraud or manipulation in less regulated markets.
- Verify the company's financial health through available reports.
- Assess the management team's track record and experience.
- Research market trends and competitive landscape.
- Evaluate the company's growth strategy and potential risks.
- Monitor regulatory changes that may impact the business.
- Established history and reputation in the healthcare sector.
- Transparency in financial reporting and corporate governance.
- Positive customer testimonials and case studies.
- Partnerships with reputable healthcare institutions.
What Investors Ask About Pro Medicus Limited (PMCUF) — Healthcare
Is PMCUF a good stock?
Stock Expert AI does not rate PMCUF buy, sell or hold. Pro Medicus Limited has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about PMCUF stock?
Analysts generally view Pro Medicus Limited positively, citing its strong market position and innovative product offerings. Key valuation metrics, such as a P/E ratio of 64.70 and a profit margin of 97.6%, indicate strong financial health.
What are the key factors to evaluate for PMCUF?
Evaluate PMCUF on fundamentals, analyst consensus, and risk factors. P/E: 64.70x vs the S&P 500's ~20-25x. Analysts target $155.00 (+31%). Not financial advice.
How frequently does PMCUF data refresh on this page?
PMCUF's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven PMCUF's recent stock price performance?
Pro Medicus Limited (PMCUF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: High profit margins indicating strong operational efficiency. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PMCUF overvalued or undervalued right now?
Pro Medicus Limited (PMCUF) trades at 64.70x earnings. Analysts target $155.00 (+31%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of PMCUF?
Yes, most major brokerages offer fractional shares of Pro Medicus Limited (PMCUF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track PMCUF's earnings and financial reports?
Pro Medicus Limited (PMCUF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for PMCUF earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data is based on the latest available information as of March 2026.